Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
OtherPractice

Antiseizure drugs for women with epilepsy

Before, during, and after pregnancy

Tejal Patel and Kelly Grindrod
Canadian Family Physician April 2020, 66 (4) 266-269;
Tejal Patel
Pharmacist and Assistant Clinical Professor, University of Waterloo School of Pharmacy in Ontario.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelly Grindrod
Pharmacist and Associate Professor, University of Waterloo School of Pharmacy in Ontario.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • CFPlus
  • eLetters
  • Info & Metrics
  • PDF
Loading

A similar number of men and women have epilepsy.1,2 However, the use of antiseizure drugs can be more complicated in women for various reasons. For example, hormonal changes can affect seizure control and the metabolism of antiseizure drugs, and there are many interactions between antiseizure drugs and hormonal contraception. Antiseizure drugs can also increase the risk of osteoporotic fractures later in life3 and increase the risk of birth defects if taken during pregnancy.2,4 To support clinicians in caring for women who take antiseizure drugs, we developed a patient-friendly infographic. The infographic focuses on 2 topics: the use of antiseizure drugs in pregnancy and breastfeeding (Figure 1)* and antiseizure drug interactions with hormonal contraception (Figure 2). Both figures are also available from CFPlus.*

Figure 1
  • Download figure
  • Open in new tab
Figure 1
Figure 2
  • Download figure
  • Open in new tab
Figure 2

Antiseizure drugs in pregnancy

All women with epilepsy of childbearing age should receive preconception counseling and should be encouraged to start planning for a pregnancy at least 1 to 2 years in advance.2,5–8 First, women should be aware that all antiseizure drugs increase the risk of birth defects, and that valproate (valproic acid, divalproex acid) has the highest risk and should be avoided in pregnancy.9–11 The Ontario treatment guidelines can be useful for choosing safer alternatives for different seizure types or epilepsy syndromes.11 Second, the risk of teratogenicity with antiseizure drugs is dose related,12 and each drug carries its own risks. Where possible, women with epilepsy who are planning for a pregnancy should take the fewest number of drugs at the lowest effective doses needed for seizure control. Third, they should aim to be seizure free for at least 9 months before pregnancy, as this increases the likelihood they will remain seizure free during pregnancy.13 Finally, many antiseizure drugs affect folic acid levels, and planning ahead allows women to start folic acid supplementation. Use folic acid doses of at least 0.4 mg daily, or up to 5 mg daily for women who have a higher risk of offspring with neural tube defects or to reduce the risk of cognitive effects in the offspring from antiseizure drugs.2,3,7,11 Thus, a woman who takes valproate for seizures, for example, should be aware that if she wishes to become pregnant, she will need time to taper the valproic acid, start a safer alternative, optimize the dose for seizure control, be seizure free for at least 9 months before pregnancy, and start taking folic acid.

During pregnancy, antiseizure drugs should not be stopped or switched, as that can lead to poor seizure control. As the risk of teratogenicity increases with dose, doses should also be increased cautiously. That said, antiseizure drug doses might occasionally need to be adjusted in response to the physiological changes of pregnancy.2,3,7 For example, the serum concentrations of levetiracetam and lamotrigine will often decline during pregnancy. Women who experience seizures when serum drug concentrations fall might need a higher drug dose. Women who have complete seizure control despite a drop in their serum drug concentration do not necessarily need a higher dose. Doses adjusted during pregnancy might also need to be decreased again after the baby is born.3 Of note, while the total concentration of phenytoin might also decline, the free phenytoin concentration is a more useful measure, as it often remains unchanged. As with other drugs, if a woman experiences seizures when the free phenytoin concentration falls, she might need a higher dose.

Finally, most antiseizure drugs are considered to be safe or moderately safe for breastfeeding, although ethosuximide is contraindicated.14 Clinicians should advise women who breastfeed while taking antiseizure drugs to monitor for signs of toxicity in infants, such as abnormal muscle tone, poor feeding and growth, or sedation.14

Antiseizure drugs and birth control

Copper intrauterine devices (IUDs) and levonorgestrel IUDs are the only 2 forms of contraception that are unaffected by antiseizure drugs. Many antiseizure drugs are potent inducers of the cytochrome P450 enzymes, meaning they increase the number of metabolizing enzymes in the liver.2,3,15–17 Estrogen (and progesterone to a lesser extent) is primarily metabolized by cytochrome P450 3A4 enzymes, although 2C9, 2C19, and 3A5 might also play a role. As a result, when oral combined hormonal contraceptives are taken together with an enzyme inducer such as carbamazepine or phenytoin, the increased first-pass hepatic metabolism lowers the estrogen serum concentrations and increases the risk of unplanned pregnancy. Women who take oral combined hormonal contraceptives should use a product with at least 30 µg of ethinyl estradiol. While some authors recommend using at least 50 µg of ethinyl estradiol,16,18 there are no products with this amount of ethinyl estradiol available in Canada. Women might also prefer tri-cycling or long-cycling, where a pill is taken daily with a pill-free interval of 4 to 7 days, every 3 months.18 Alternatively, women could choose medroxyprogesterone acetate intramuscular injections, which can be administered every 10 to 12 weeks.16 Women who opt for non-IUD hormonal contraception can also further decrease their risk of pregnancy by using a barrier method.

In contrast to the above interaction, estrogen can also increase the metabolism of lamotrigine and valproic acid.17 A woman who is seizure free while taking either lamotrigine or valproic acid might experience an increase in seizure frequency after starting an estrogen product. In these cases, the dose of valproate or lamotrigine can be increased as needed for the control of seizures.

Other considerations

The interaction between estrogen and antiseizure drugs also has implications beyond the childbearing years. For example, women who use estrogen for menopausal hot flashes might need higher doses if they use an enzyme-inducing antiseizure drug. Similarly, women who have used antiseizure drugs for many years have a higher risk of osteoporotic fractures, both due to falls from seizures and to the effects antiseizure drugs on bone health.4 All women who take antiseizure drugs should ensure they get enough calcium, vitamin D, and exercise. Finally, many women take antiseizure drugs for various indications including chronic pain, mood, and headache. These women face will similar challenges to those faced by women with epilepsy.

Conclusion

There are many special considerations for women who use antiseizure drugs, regardless of the indication. Clinicians should ensure that they take the time to educate all women who use these drugs on the effects the drugs can have on contraception, pregnancy, breastfeeding, and hormones later in life.

Acknowledgments

We thank Adrian Poon for designing the infographic, and Jessica Ivo, Sadaf Faisal, Rosemary Killeen, Dr Eduard Bercovici, and the women with epilepsy, pharmacists, family physicians, and neurologists who reviewed it. This work was funded through a grant from the Women’s Xchange through Women’s College Hospital in Toronto, Ont.

Notes

We encourage readers to share some of their practice experience: the neat little tricks that solve difficult clinical situations. Praxis articles can be submitted online at http://mc.manuscriptcentral.com/cfp or through the CFP website (www.cfp.ca) under “Authors and Reviewers.”

Footnotes

  • ↵* The infographics on use of antiseizure drugs in pregnancy and breastfeeding (Figure 1) and antiseizure drug interactions with hormonal contraception (Figure 2) are available at www.cfp.ca. Go to the full text of the article online and click on the CFPlus tab.

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    1. Fiest KM,
    2. Sauro KM,
    3. Wiebe S,
    4. Patten SB,
    5. Kwon CS,
    6. Dykeman J,
    7. et al
    . Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology 2017;88(3):296-303. Epub 2016 Dec 16. Erratum in: Neurology 2017;89(6):642.
    OpenUrlCrossRef
  2. 2.↵
    1. Gooneratne IK,
    2. Wimalaratna S
    . Update on management of epilepsy in women for the non-neurologist. Postgrad Med J 2016;92(1091):554-9. Epub 2016 Jul 13.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Shiek Ahmad B,
    2. Hill KD,
    3. O’Brien TJ,
    4. Gorelik A,
    5. Habib N,
    6. Wark JD
    . Falls and fractures in patients chronically treated with antiepileptic drugs. Neurology 2012;79(2):145-51. Epub 2012 Jun 13.
    OpenUrl
  4. 4.↵
    1. Stephen LJ,
    2. Harden C,
    3. Tomson T,
    4. Brodie MJ
    . Management of women in epilepsy. Lancet Neurol 2019;18(5):481-91. Epub 2019 Mar 8.
    OpenUrl
  5. 5.↵
    1. Bhakta J,
    2. Bainbridge J,
    3. Borgelt L
    . Teratogenic medications and concurrent contraceptive use in women of childbearing ability with epilepsy. Epilepsy Behav 2015;52(Pt A):212-7. Epub 2015 Nov 6.
    OpenUrl
  6. 6.
    1. Harden CL,
    2. Pennell PB,
    3. Koppel BS,
    4. Hovinga CA,
    5. Gidal B,
    6. Meador KJ,
    7. et al
    . Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding. Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009;73(2):142-9. Epub 2009 Apr 27.
    OpenUrl
  7. 7.↵
    1. Abe A,
    2. Hamada H,
    3. Tamada T,
    4. Obata-Yasuoka M,
    5. Minakami H,
    6. Yoshikawa H
    . Impact of planning of pregnancy in women with epilepsy on seizure control during pregnancy and on maternal and neonatal outcomes. Seizure 2014;23(2):112-6. Epub 2013 Oct 17.
    OpenUrl
  8. 8.↵
    1. Borgelt LM,
    2. Hart FM,
    3. Bainbridge JL
    . Epilepsy during pregnancy: focus on management strategies. Int J Womens Health 2016;8:505-17.
    OpenUrl
  9. 9.↵
    1. Tomson T,
    2. Battino D
    . Teratogenic effects of antiepileptic drugs. Lancet Neurol 2012;11(9):803-13. Epub 2012 Jul 16.
    OpenUrlCrossRefPubMed
  10. 10.
    1. Harden CL,
    2. Hopps J,
    3. Ting TY,
    4. Pennell PB,
    5. French JA,
    6. Hauser WA,
    7. et al
    . Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes. Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009;73(2):133-41. Epub 2009 Apr 27.
    OpenUrlCrossRef
  11. 11.↵
    1. Epilepsy Implementation Task Force, Provincial Neurosurgery Ontario.
    Provincial guidelines for the management of epilepsy in adults and children. Toronto, ON: Critical Care Services Ontario; 2015.
  12. 12.↵
    1. Tomson T,
    2. Battino D,
    3. Bonizzoni E,
    4. Craig J,
    5. Lindhout D,
    6. Sabers A,
    7. et al
    . Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011;10(7):609-17. Epub 2011 Jun 5.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Harden CL,
    2. Hopp J,
    3. Ting TY,
    4. Pennell PB,
    5. French JA,
    6. Hauser WA,
    7. et al
    . Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency. Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009;73(2):126-32. Epub 2009 Apr 27.
    OpenUrl
  14. 14.↵
    1. Davanzo R,
    2. Dal Bo S,
    3. Bua J,
    4. Copertino M,
    5. Zanelli E,
    6. Matarazzo L
    . Antiepileptic drugs and breastfeeding. Ital J Pediatrics 2013;39:50.
    OpenUrl
  15. 15.↵
    1. Reimers A,
    2. Brodtkorb E,
    3. Sabers A
    . Interactions between hormonal contraception and antiepileptic drugs: clinical and mechanistic considerations. Seizure 2015;28:66-70. Epub 2015 Mar 20.
    OpenUrl
  16. 16.↵
    1. Schwenkhagen AM,
    2. Stodieck SRG
    . Which contraception for women with epilepsy. Seizure 2008;17(2):145-50. Epub 2008 Jan 4.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Reddy DS
    . Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives. Expert Rev Clin Pharmacol 2010;3(2):183-92.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Gooneratne IK,
    2. Wimalaratna M,
    3. Ranaweera AKP,
    4. Wilamaratna S
    . Contraception advice for women with epilepsy. BMJ 2017;357:j2010.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Canadian Family Physician: 66 (4)
Canadian Family Physician
Vol. 66, Issue 4
1 Apr 2020
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Antiseizure drugs for women with epilepsy
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Antiseizure drugs for women with epilepsy
Tejal Patel, Kelly Grindrod
Canadian Family Physician Apr 2020, 66 (4) 266-269;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Antiseizure drugs for women with epilepsy
Tejal Patel, Kelly Grindrod
Canadian Family Physician Apr 2020, 66 (4) 266-269;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Antiseizure drugs in pregnancy
    • Antiseizure drugs and birth control
    • Other considerations
    • Conclusion
    • Acknowledgments
    • Notes
    • Footnotes
    • References
  • Figures & Data
  • CFPlus
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Practice

  • Is 45 the new 50 in colorectal cancer screening?
  • Approach to diagnosis and management of childhood attention deficit hyperactivity disorder
  • Determining if and how older patients can safely stay at home with additional services
Show more Practice

Praxis

  • Aide à la décision d’utiliser ou non les gliflozines pour l’insuffisance cardiaque avec fraction d’éjection supérieure à 40 %, à l’intention des patients
  • Patient decision aid for flozins in heart failure and ejection fraction greater than 40%
  • Examens et traitements à reconsidérer en médecine du sport et de l’exercice pédiatrique
Show more Praxis

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2023 by The College of Family Physicians of Canada

Powered by HighWire